Carlsmed, Inc. (NASDAQ:CARL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Carlsmed, Inc. (NASDAQ:CARL) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $19.25.

A number of research firms have recently weighed in on CARL. Truist Financial increased their price target on Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Needham & Company LLC initiated coverage on Carlsmed in a report on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price objective for the company. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th.

Carlsmed Stock Up 0.1%

Shares of NASDAQ:CARL opened at $15.60 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The stock has a market cap of $425.88 million, a price-to-earnings ratio of -10.91 and a beta of 1.95. The company has a 50 day moving average of $14.12 and a 200-day moving average of $11.96. Carlsmed has a one year low of $8.50 and a one year high of $17.23.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The business had revenue of $18.94 million for the quarter. On average, sell-side analysts forecast that Carlsmed will post -1.5 earnings per share for the current year.

Hedge Funds Weigh In On Carlsmed

Several institutional investors and hedge funds have recently modified their holdings of CARL. Deutsche Bank AG acquired a new stake in Carlsmed during the 2nd quarter worth approximately $106,000. Bank of America Corp DE acquired a new position in shares of Carlsmed in the second quarter valued at approximately $108,000. Alpine Woods Capital Investors LLC bought a new stake in shares of Carlsmed during the second quarter worth $161,000. Bank of New York Mellon Corp bought a new stake in shares of Carlsmed during the second quarter worth $181,000. Finally, Sectoral Asset Management Inc. acquired a new stake in shares of Carlsmed during the fourth quarter worth $589,000.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on improving outcomes for patients undergoing complex spinal surgery. The company develops personalized implants and surgical solutions designed to help spine surgeons address the anatomical needs of individual patients, particularly those with adult spinal deformity and other challenging spinal conditions.

Its principal product platform, aprevo, uses patient-specific planning and implant design to support spinal reconstruction procedures.